News coverage about Invivo Therapeutics (NASDAQ:NVIV) has trended somewhat negative on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Invivo Therapeutics earned a daily sentiment score of -0.06 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.0197498162228 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Invivo Therapeutics (NVIV) versus Its Rivals Financial Review (americanbankingnews.com)
- BRIEF-InVivo Therapeutics Announces Executive Management And Board Changes (reuters.com)
- Invivo Therapeutics (NVIV) Appoints Richard Toselli, MD as CEO Following Resignation for Mark Perrin from CEO and … – StreetInsider.com (streetinsider.com)
- InVivo Therapeutics Announces Executive Management and Board Changes (finance.yahoo.com)
- Analyzing Invivo Therapeutics (NVIV) and Its Peers (americanbankingnews.com)
Separately, ValuEngine lowered Invivo Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Invivo Therapeutics (NASDAQ:NVIV) last issued its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). equities research analysts forecast that Invivo Therapeutics will post -0.81 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Critical Media Coverage Somewhat Unlikely to Affect Invivo Therapeutics (NVIV) Share Price” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/12/20/somewhat-critical-media-coverage-somewhat-unlikely-to-affect-invivo-therapeutics-nviv-share-price.html.
Invivo Therapeutics Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.